Related references
Note: Only part of the references are listed.Correlation Between Hemoglobin Levels and the Prognosis of First-Line Chemotherapy in Patients with Advanced Gastric Cancer
Qing Wei et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
K. Kato et al.
ANNALS OF ONCOLOGY (2020)
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Zhibo Zhang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer
Megan Greally et al.
CLINICAL CANCER RESEARCH (2019)
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
N. Boku et al.
ANNALS OF ONCOLOGY (2019)
Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy
Michael R. Clausen et al.
CLINICAL EPIDEMIOLOGY (2019)
Immunotherapy for metastatic renal cell carcinoma: A systematic review
Frank Peinemann et al.
JOURNAL OF EVIDENCE BASED MEDICINE (2019)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer
Patrick M. Cotogno et al.
ONCOLOGIST (2018)
Biomarkers of gastric cancer: Current topics and future perspective
Tasuku Matsuoka et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells
Lintao Zhao et al.
NATURE MEDICINE (2018)
The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis
Yaqi Huang et al.
BMC CANCER (2018)
Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment
Kaitlin Graham et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Advances in Immunotherapy for Melanoma: A Comprehensive Review
Carmen Rodriguez-Cerdeira et al.
MEDIATORS OF INFLAMMATION (2017)
Cost-Effectiveness of Nivolumab-lpilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States
Anna Oh et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2017)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Scott Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The Platelet-to-Lymphocyte Ratio Versus Neutrophil-to-Lymphocyte Ratio: Which is Better as a Prognostic Factor in Gastric Cancer?
Eun Young Kim et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Update on Metastatic Gastric and Esophageal Cancers
Manish A. Shah
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer
Y. Yamada et al.
ANNALS OF ONCOLOGY (2015)
Diagnosis and treatment of cancer-related anemia
Jeffrey A. Gilreath et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non-Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy
Mizuki Nishino et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2010)
Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy
SJP Van Belle et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2003)
Anemia in oncology practice - Relation to diseases and their therapies
F Tas et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2002)
Anemia as an independent prognostic factor for survival in patients with cancer
J Watine et al.
CANCER (2002)
Impact of tumor hypoxia and anemia on radiation therapy outcomes
LB Harrison et al.
ONCOLOGIST (2002)
Share Paper
